My Account | Shopping Cart | Contact

OligoBuilder® | Nucleotides List | Stocked mRNA List | DNA Synthesis Reagents List | CleanAmp™ Products List


You are at: All > Oligonucleotides > Custom Oligonucleotide Components by Type > Backbones (Purification Options & Expected Yields)

Phosphorothioate DNA
PS DNA, S-Oligo, Phosphorothioate Oligonucleotide, Thioate

Phosphorothioate DNA

Per Base Pricing
0.2 µmole $4.50
1.0 µmole $6.00
5.0 µmole $12.00
10 µmole $16.00
15 µmole $20.00


Purification Method0.2 µmole1.0 µmole
Double RP-HPLC$100$150               
Single RP-HPLC & RP-Cartridge$50$75
AX-HPLC$75$125
RP-Cartridge$20$20
PAGE$75$125
 
Purification Method5.0 µmole10 µmole15 µmole
Double RP-HPLC$275$325$375
Single RP-HPLC & RP-Cartridge$225$275$325
AX-HPLC$275$375$425
RP-CartridgeN/AN/AN/A
PAGE$500$750$1000


Expected Yields*OD260 unitsapprox. mg
0.2 μmole scale5 - 150.15 - 0.50
1.0 μmole scale20 - 600.66 - 2.00
5.0 μmole scale100-2503.33 - 8.33
10 μmole scale200-5006.66 - 16.6
15 μmole scale300-75010.0 - 25.0

*Expected yields are estimates for HPLC purified (~90%) unmodified oligonucleotides. Yield and purity differences can be caused by many factors, such as sequence and length. If you require a specific yield, please let us know when you place your order or request a quote.
 
 
The modification of oligonucleotides by exchanging a non-bridging oxygen on the phosphate backbone to form a phosphorothioate (PS) linkage has a long history. Initially introduced and explored by Prof. Fritz Eckstein mainly with modified nucleoside triphosphates in the 1970’s, the most significant application was described in the early 1980’s by a team from the NCI and NIH. They demonstrated the use of a phosphorothioate linkage to protect antisense oligonucleotides from nuclease degradation, prolonging it’s lifetime in serum.
 
To this day, the main application of phosphorothioate linkages in an oligo is to protect the oligo from nuclease degradation. It is the least expensive option and is fairly effective, although nuclease resistance is often further enhanced when combined with a 2’-OMe (2' O-Methyl ) modification. Nuclease stability is essential for antisense and RNAi applications where oligos are exposed to exonucleases and endonucleases within cells. Phosphorothioates have become the most popular modification used in antisense oligonucleotides.

One drawback to adding phosphorothioate linkages is that it does destabilize duplexes, reducing the Tm (melting temperature, the temperature at which exactly one half the single strands of a duplex are hybridized) by 1-3° C per addition. This can also be largely overcome by the addition of 2’ OMe modifications which increases Tm by a similar amount. However, the portion of the oligo so modified will have properties more similar to RNA than to DNA.
 
TriLink is proud to be one of the leaders in custom phosphorothioate oligo (S-Oligo, thioate) synthesis. Our high purity standards are crucial for the synthesis of modified oligos without the cytotoxic issues that plagued PS oligonucleotides for decades. You can depend on TriLink to deliver the quality you need to succeed.





Email a Friend
Product Inquiry
    
Ready to order
your oligonucleotide?

Related Products :

Related Categories :


Reference(s)
De Cecco L, et. al. Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. PLoS One. 2013;8(3):e58849. doi: 10.1371/journal.pone.0058849.
Hayashi T, Yao S, Crain B, Chan M, Tawatao RI, Gray C, Vuong L, Lao F, Cottam HB, Carson DA, Corr M. Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune system. PLoS One. 2012;7(9):e45860. doi: 10.1371/journal.pone.0045860.
Uddin MN, et. al. Enhanced bioavailability of orally administered antisense oligonucleotide to nuclear factor kappa B mRNA after microencapsulation with albumin. J Drug Target. 2013 Mar 12. doi:10.3109/1061186X.2013.765440.
Tapia-Abellán A, et. al. The peritoneal macrophage inflammatory profile in cirrhosis dependens on the alcoholic or hepatitis C viral etiology and is related to ERK phosphorylation. BMC Immunol. 2012 Aug 6;13(1):42. doi:10.1186/1471-2172-13-42.
Kwissa M, Nakaya HI, Oluoch H, Pulendran B. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in non-human primates. Blood. 2012 Mar 1;119(9):2044-55.
Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, Gendler SJ, Mukherjee P. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother. 2012 Apr 28. doi: 10.1007/s00262-012-
Hayashi T, Yao S, Crain B, Chan M, Tawatao RI, Gray C, Vuong L, Lao F, Cottam HB, Carson DA, Corr M. Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System. PLoS One. 2012;7(9):e45860. doi: 10.1371/journal.pone.0045860.
Sun Y, Zhang Z, Grigoryants VM, Myers WK, Liu F, Earle KA, Freed JH, Scholes CP. The Internal Dynamics of Mini c TAR DNA Probed by EPR of Nitroxide Spin Labels at the Lower Stem, the Loop, and the Bulge. Biochemistry. 2012 Sep 25. doi: 10.1021/bi301058q.
Freed DC, Towne VM, Casimiro DR, Zhao Q, Fu TM. Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations. (2011) Vaccine. doi:10.1016/j.vaccine.2011.09.122 Oct 11. [Epub a
Awasthi S, et. al. Immunization with a Vaccine Combining Herpes Simplex Virus 2 (HSV-2) Glycoprotein C (gC) and gD Subunits Improves the Protection of Dorsal Root Ganglia in Mice… . (2011) Journal of Virology, 85(20), 10472-10486.
Kogut MH, He H, Genovese KJ. Bacterial toll-like receptor agonists induce sequential NF-κB-mediated leukotriene B(4) and prostaglandin E(2) production in chicken heterophils. Vet Immunol Immunopathol. 2011 Nov 11. doi:10.1016/j.vetimm.2011.11.003
Hayashi T, Rao SP, Takabayashi K, Van Uden JH, Kornbluth RS, Baird SM, Taylor MW, Carson DA, Catanzaro A, Raz E. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infe


 

 


  Twitter Twitter Facebook Facebook Linked In Linked In RSS RSS Google RSS  
© 2014 TriLink BioTechnologies, Inc. | All Rights Reserved